Lifestyle Kit
OtherThe investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
NCT Number: NCT06483711
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of liver disease in the world. It is estimated that 38% of American children with obesity have steatotic liver disease. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. This study intends to provide insight to barriers of recommended care for pediatric patients with Hispanic ethnicity and a new diagnosis of MASLD. The investigators propose to augment existing structural barriers related to health literacy, food accessibility and dietary knowledge, and access to safe physical activity through a healthy lifestyle toolkit and individualized nutritional counseling.
Trial opening soon.
Get Notified10 year–17 year
All sexes
Interventional
Not applicable
The Hispanic population represents the largest and fastest growing ethnic group in the United States. Patients of Hispanic ethnicity are disproportionately at risk of developing MASLD. An adult meta-analysis found a prevalence rate of 22.9% among individuals of Hispanic ethnicity. A pediatric retrospective study found that children who are Hispanic are 5 times more likely to have MASLD than their age/gender matched peers who identify as black. The etiology of why individuals of Hispanic ethnicity are at higher risk of developing MASLD, and subsequently associated co-morbidities such as insulin resistance, diabetes, and cardiovascular disease, is thought to be multifactorial. There is evidence to suggest that individuals of Hispanic ethnicity have a genetic predisposition for hepatic fat infiltration.11 Additionally, it has been postulated that social determinants of health, such as economic stability and health care access and quality contribute to an increased risk.
The American Association for the Study of Liver Diseases (AASLD) recommends lifestyle modification as the foundation of treatment for MASLD. Implementing dietary changes and increasing physical activity contribute to weight loss, which has been found to reduce hepatic steatosis. A 7-10% weight loss can improve histopathological features of MASLD, including fibrosis.Application of dietary modification, such as adherence to the Mediterranean dietary pattern, can decrease hepatic fat content, even in the absence of weight loss.Though lifestyle intervention has been found to be effective, barriers to implementation exist. In a study of adult patients of Hispanic ethnicity with a diagnosis of MASLD, access to nutritious food and a safe exercising environment limited the ability to follow through with recommended lifestyle changes.A survey study of pediatric patients with MASLD found that many lacked the opportunity for physical activity, though the majority expressed an interest in participation.16 Health literacy, or the ability to obtain and comprehend medical information, has also been found to be a barrier to effective care. In a qualitative interview study of adults with MASLD, health literacy was hindered by the availability of liver disease resources in the patient's preferred language. There is limited pediatric data regarding perceived barriers to implementing lifestyle changes. With this study, the investigators hope to minimize some of the social determinants of health that can impact Hispanic pediatric MASLD patients and help them participate in the recommended standard of care.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The investigators will provide a kit to families that contains educational information, exercise equipment, and nutritional products.
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Social Determinants of Health Screener will identify the presence of food, housing, and/or transportation insecurity.
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
AST lab value
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
ALT Lab value
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
GGT Lab value
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
BMI
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
weight
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
Socioeconomic status
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
ethnic background
Time frame: Baseline and month 3 or 6 depending on when the participant's follow up appointment with the physician is scheduled.
primary language
Contact information is provided by the study sponsor or research team.
Amrita Narang, MD
CONTACT
Rachel Herdes, DO
CONTACT
Stanford University
Other
Reducing Barriers to Lifestyle Modification for Pediatric Patients of Hispanic Ethnicity and Newly Diagnosed MASLD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731360
Body Weight, Digestive System Diseases
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT07731373
46, XX Disorders of Sex Development, Adnexal Diseases
Kayseri, Turkey (Türkiye)
View Trial DetailsNCT07716995
Apnea, Dyssomnias
View Trial DetailsNCT07706010
Diabetes Mellitus, Diabetes Mellitus, Type 2
Hanzhou, Zhejiang, China
View Trial Details